This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.
UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
UCB Achieves Important Regulatory Milestone for Bimekizumab
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances
• Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration
Press Release: Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo